Global Innovative Platforms Inc. Files 2023 10-K

TL;DR

GIP filed its 2023 10-K. Financials and biz ops for FY ending 9/30/23 are out.

AI Summary

Global Innovative Platforms Inc. filed its 2023 10-K on August 23, 2024, reporting on its fiscal year ending September 30, 2023. The company, formerly known as Canning Street Corp, is incorporated in Delaware and operates in the real estate and construction sector. Its principal executive offices are located at 149 James Place, Maitland, FL 32751.

Why It Matters

This filing provides a comprehensive overview of Global Innovative Platforms Inc.'s financial performance and business operations for the fiscal year 2023, crucial for investors and stakeholders to assess the company's health and future prospects.

Risk Assessment

Risk Level: low — The provided text is a standard 10-K filing header and does not contain specific financial performance data or forward-looking statements that would indicate a high risk level.

Key Players & Entities

• Global Innovative Platforms Inc. (company) — Filer
• Canning Street Corp (company) — Former Company Name
• 20230930 (date) — Fiscal Year End
• 20240823 (date) — Filing Date
• 149 James Place, Maitland, FL 32751 (address) — Business and Mail Address

FAQ

Key Financial Figures

• $0.0001 — e Exchange Act: Common Stock, par value $0.0001 per share Indicate by check mark if t
• $30 — ted for heartworm annually at a cost of $30 to $50 per test. Approximately One perc
• $50 — heartworm annually at a cost of $30 to $50 per test. Approximately One percent of
• $50,000 — as agreed to make an initial payment of $50,000, which is due 30 days from the effectiv
• $225,000 — Agreement (or, at Defiant's discretion, $225,000 in a lump sum within 45 days from the e
• $1,000,000,000 — JOBS Act") as we did not have more than $1,000,000,000 in annual gross revenue and did not hav

Filing Documents

• e5885_10-k.htm (10-K) — 583KB
• e5885_ex31-1.htm (EX-31.1) — 8KB
• e5885_ex32-1.htm (EX-32.1) — 4KB
• image_001.jpg (GRAPHIC) — 1KB
• 0001731122-24-001311.txt ( ) — 2257KB
• cstc-20230930.xsd (EX-101.SCH) — 20KB
• cstc-20230930_cal.xml (EX-101.CAL) — 24KB
• cstc-20230930_def.xml (EX-101.DEF) — 30KB
• cstc-20230930_lab.xml (EX-101.LAB) — 140KB
• cstc-20230930_pre.xml (EX-101.PRE) — 111KB
• e5885_10-k_htm.xml (XML) — 174KB

FORWARD-LOOKING STATEMENTS

FORWARD-LOOKING STATEMENTS of the Exchange Act, this Form 10-K contains forward-looking statements. The forward-looking statements are based on our current goals, plans, expectations, assumptions, estimates and predictions regarding the Company. When used in this Annual Report, the words "plan", "believes," "continues," "expects," "anticipates," "estimates," "intends", "should," "would," "could," or "may," and similar expressions are intended to identify forward looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or growths to be materially different from any future results, events or growths expressed or implied in this Annual Report. In this Annual Report on Form 10-K, "Global Innovative Platforms," the "Company,' we,'' us,'' and our,'' refer to Global Innovative Platforms, Inc., unless the context otherwise requires. Unless otherwise indicated, the term fiscal year' refers to our fiscal year ending September 30 th . Unless otherwise indicated, the term common stock'' refers to shares of the Company's common stock. TABLE OF CONTENTS GLOBAL INNOVATIVE PLATFORMS, INC. PART I PAGE ITEM 1

BUSINESS

BUSINESS 1 ITEM 1A

RISK FACTORS

RISK FACTORS 7 ITEM 1B UNRESOLVED STAFF COMMENTS 17 ITEM 2

PROPERTIES

PROPERTIES 17 ITEM 3

LEGAL PROCEEDINGS

LEGAL PROCEEDINGS 17 ITEM 4 MINE SAFETY DISCLOSURES 17 PART II 18 ITEM 5 MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES 18 ITEM 6 RESERVED 21 ITEM 7

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 21 ITEM 7A

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 27 ITEM 8

FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA 27 ITEM 9 CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE 27 ITEM 9A

CONTROLS AND PROCEDURES

CONTROLS AND PROCEDURES 27 ITEM 9B OTHER INFORMATION 28 ITEM 9C DICLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS 28 PART III 29 ITEM 10 DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE 29 ITEM 11

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 32 ITEM 12

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS 34 ITEM 13 CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE 35 ITEM 14 PRINCIPAL ACCOUNTING FEES AND SERVICES 35 PART IV 36 ITEM 15 EXHIBITS, FINANCIAL STATEMENT SCHEDULES 36

SIGNATURES

SIGNATURES 37 i PART I ITEM 1. BUSINESS. Nature of Business Global Innovative Platforms Inc. f/k/a Canning Street Corporation, a Delaware corporation, ( "Global Innovative Platforms"," Canning Street," "we," "us" or "our") is engaged in the business of testing breath to detect and assist in the treatment of disease. Overview Advancements in technology have opened up numerous opportunities in the area of detecting and analyzing gasses for health related information. Various tests and devices have been developed over the years that monitor air quality and assist in the diagnosis and treatment of disease. Many diseases and conditions leave indications of their presence in the form of Volatile Organic Compounds (VOCs) that occur in various patterns we call breath prints. Equipment has evolved to capture these prints and new Machine Learning technologies (Artificial Intelligence) are able to detect such patterns using sampling. The mere existence of the VOC is of some value but other factors such as timing, combinations with other VOCs and quantities of VOCS are also of importance. We are a medical technology company focused on applying these advancements in animals and agriculture, We have identified several opportunities and are prioritizing the development of a breath test to replace adult female heartworm antigen blood tests to detect heartworm in dogs. The current leading heartworm test, Female Antigen testing requires the heartworm itself to be 6 months old in order to be detected. Breath analytics involves the collection, processing, and analysis of breath samples to identify biomarker patterns associated with heartworms and ultimately other diseases in dogs (including other agricultural applications as well). Since the test can directly evaluating the heartworm at all stages of its life rather than full maturity, the 6 month requirement is no longer applicable, the population of undetected cases can be reduced, and the suffering of animals can be r

View Full Filing

View this 10-K filing on SEC EDGAR